Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial

Background and Aims: Previous studies suggest that administration of vecuronium based on total body weight rather than ideal body weight (IBW) in obesity results in overdosing with prolonged recovery times. We hypothesised that larger doses of neostigmine could result in faster recovery in obese pat...

Full description

Bibliographic Details
Main Authors: Satyen Parida, Venkatesan Kausalya, Sandeep Kumar Mishra, Sethuramachandran Adinarayanan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Indian Journal of Anaesthesia
Subjects:
Online Access:http://www.ijaweb.org/article.asp?issn=0019-5049;year=2017;volume=61;issue=10;spage=787;epage=792;aulast=Parida
id doaj-9dcbbc681a6b4fe79cd8a3fc2267233e
record_format Article
spelling doaj-9dcbbc681a6b4fe79cd8a3fc2267233e2020-11-25T01:51:52ZengWolters Kluwer Medknow PublicationsIndian Journal of Anaesthesia0019-50490976-28172017-01-01611078779210.4103/ija.IJA_297_17Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trialSatyen ParidaVenkatesan KausalyaSandeep Kumar MishraSethuramachandran AdinarayananBackground and Aims: Previous studies suggest that administration of vecuronium based on total body weight rather than ideal body weight (IBW) in obesity results in overdosing with prolonged recovery times. We hypothesised that larger doses of neostigmine could result in faster recovery in obese patients administered vecuronium based on total body weight. Methods: Forty-five obese American Society of Anesthesiologists' II patients undergoing elective surgery under general anaesthesia were randomised into 3 groups to receive neostigmine 30, 40 and 50 μg/kg. Following induction, patients were paralysed with vecuronium 0.1 mg/kg based on total body weight. Reversal was achieved with neostigmine based on the patient's group, and time to train-of-four (TOF) ratios of 0.5, 0.7 and 0.9 measured. The primary outcome variable was time to achieve TOF ratio >0.9. Results: Neostigmine 50 μg/kg achieved faster recovery to TOF 0.7 than neostigmine 30 and 40 μg/kg. There was no significant difference in recovery times to TOF 0.7 in patients receiving either 30 or 40 μg/kg of neostigmine. However, neostigmine 40 μg/kg attained TOF ratio 0.9 faster than 30 μg/kg. We did not note a significant difference between the 40 and 50 μg/kg dose with regard to recovery of TOF to 0.9. Conclusion: Facilitated recovery from neuromuscular blockade to TOF of 0.7 was faster with neostigmine 50 μg/kg compared to 40 or 30 μg/kg. Recovery to TOF ratio of 0.9 was not significantly different with 40 or 50 μg/kg doses although such time was faster as compared to 30 μg/kg dose.http://www.ijaweb.org/article.asp?issn=0019-5049;year=2017;volume=61;issue=10;spage=787;epage=792;aulast=ParidaNeostigmineobesityvecuronium bromide
collection DOAJ
language English
format Article
sources DOAJ
author Satyen Parida
Venkatesan Kausalya
Sandeep Kumar Mishra
Sethuramachandran Adinarayanan
spellingShingle Satyen Parida
Venkatesan Kausalya
Sandeep Kumar Mishra
Sethuramachandran Adinarayanan
Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial
Indian Journal of Anaesthesia
Neostigmine
obesity
vecuronium bromide
author_facet Satyen Parida
Venkatesan Kausalya
Sandeep Kumar Mishra
Sethuramachandran Adinarayanan
author_sort Satyen Parida
title Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial
title_short Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial
title_full Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial
title_fullStr Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial
title_full_unstemmed Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial
title_sort dose-reversal effect relationship of three different doses of neostigmine in obese patients: a randomised clinical trial
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Anaesthesia
issn 0019-5049
0976-2817
publishDate 2017-01-01
description Background and Aims: Previous studies suggest that administration of vecuronium based on total body weight rather than ideal body weight (IBW) in obesity results in overdosing with prolonged recovery times. We hypothesised that larger doses of neostigmine could result in faster recovery in obese patients administered vecuronium based on total body weight. Methods: Forty-five obese American Society of Anesthesiologists' II patients undergoing elective surgery under general anaesthesia were randomised into 3 groups to receive neostigmine 30, 40 and 50 μg/kg. Following induction, patients were paralysed with vecuronium 0.1 mg/kg based on total body weight. Reversal was achieved with neostigmine based on the patient's group, and time to train-of-four (TOF) ratios of 0.5, 0.7 and 0.9 measured. The primary outcome variable was time to achieve TOF ratio >0.9. Results: Neostigmine 50 μg/kg achieved faster recovery to TOF 0.7 than neostigmine 30 and 40 μg/kg. There was no significant difference in recovery times to TOF 0.7 in patients receiving either 30 or 40 μg/kg of neostigmine. However, neostigmine 40 μg/kg attained TOF ratio 0.9 faster than 30 μg/kg. We did not note a significant difference between the 40 and 50 μg/kg dose with regard to recovery of TOF to 0.9. Conclusion: Facilitated recovery from neuromuscular blockade to TOF of 0.7 was faster with neostigmine 50 μg/kg compared to 40 or 30 μg/kg. Recovery to TOF ratio of 0.9 was not significantly different with 40 or 50 μg/kg doses although such time was faster as compared to 30 μg/kg dose.
topic Neostigmine
obesity
vecuronium bromide
url http://www.ijaweb.org/article.asp?issn=0019-5049;year=2017;volume=61;issue=10;spage=787;epage=792;aulast=Parida
work_keys_str_mv AT satyenparida dosereversaleffectrelationshipofthreedifferentdosesofneostigmineinobesepatientsarandomisedclinicaltrial
AT venkatesankausalya dosereversaleffectrelationshipofthreedifferentdosesofneostigmineinobesepatientsarandomisedclinicaltrial
AT sandeepkumarmishra dosereversaleffectrelationshipofthreedifferentdosesofneostigmineinobesepatientsarandomisedclinicaltrial
AT sethuramachandranadinarayanan dosereversaleffectrelationshipofthreedifferentdosesofneostigmineinobesepatientsarandomisedclinicaltrial
_version_ 1724995843096838144